Better Buy for Cautious Investors: Eli Lilly vs Costco

Costco is identified as the preferable defensive purchase over Eli Lilly, trading at about 39x forward earnings and below its typical historical valuation, while its U.S. and Canada membership renewal rate exceeds 90%. Eli Lilly retains roughly 60% U.S. GLP-1 market share, with Mounjaro and Zepbound producing more than $14 billion in recent-quarter revenue, but its valuation is described as closer to normal historical levels. The article favors Costco's membership-fee-driven profit model, resilient bargain-focused demand, and periodic special dividends, including a $15-per-share payment in 2024.

Analysis

The "defensive" framing obscures that COST carries meaningful duration risk: its earnings resilience is well understood, so a deceleration in comparable sales, renewal rates, or member penetration can produce multiple compression even if absolute earnings continue growing. The key near-term sensitivity is discretionary basket mix and traffic-to-ticket conversion; a softer consumer can preserve membership income while still limiting operating leverage through wage, shrink, and freight costs. COST is therefore a quality compounder, not a low-volatility valuation hedge.

LLY has a more asymmetric 6-18 month setup because the relevant question is not whether obesity demand exists, but whether manufacturing capacity, payer access, and pipeline differentiation extend its economic profit pool faster than consensus discounts eventual price competition. Oral obesity therapies could expand the treated population and reduce adherence friction, but they also create cannibalization and formulary-pricing risk; Novo Nordisk (NVO), not macro demand, remains the more important competitive variable. A relative LLY/COST position is preferable to outright beta: it expresses rotation from an expensive consumer-staples-like multiple into a company with multiple clinical, capacity, and indication catalysts.

Contrarian view: neither name is an obvious refuge if the market de-rates long-duration equities. In a broad real-yield shock, COST's premium multiple is likely more exposed than its recurring-fee narrative implies, while LLY's downside is concentrated around prescription-growth and gross-margin evidence rather than generalized consumer weakness. The article provides no updated prescription, supply, renewal, traffic, or valuation-history data sufficient to justify an immediate standalone entry.

Key Decisions for Investors

• Watch, do not chase COST after a defensive-flow rally; initiate only if the forward multiple compresses materially versus its own five-year range while U.S./Canada renewal and traffic remain stable. Falsifier for a long: two consecutive reports of slowing traffic or renewal deterioration, which would challenge the fee-income durability premium.
• Favor a 6-12 month pair trade: long LLY / short COST in equal dollar amounts, sized modestly until verified weekly prescription and supply data confirm continued obesity-drug volume growth. Thesis payoff comes from LLY estimate revisions and/or COST multiple normalization; exit if LLY obesity revenue growth materially misses guidance or COST delivers accelerating traffic and membership monetization.
• Maintain NVO as the primary hedge against a standalone LLY long. Escalate the hedge around obesity trial readouts, formulary decisions, or evidence of sustained net-price pressure; those events matter more to LLY's medium-term margin than broad defensive-equity sentiment.
• Set a 1-3 month alert around COST earnings for renewal rate, paid-member growth, traffic, and SG&A leverage, and around LLY earnings for volume versus realized-price growth and capacity commentary. Absent those datapoints, treat this article as low-impact sentiment rather than a fresh catalyst.